An interim analysis of the CHECKMATE920 phase IIIb/IV clinical trial found that renal cell carcinoma (RCC) patients with brain metastasis show encouraging anti-tumor activity in response to nivolumab and ipilimumab. These findings, which were presented at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, observed safety and effectiveness of nivolumab in combination with ipilimumab in patients with advanced RCC and brain metastasis, and encouraged further studies to not exclude patients with brain metastasis.

Learn more by clicking here.